الفهرس 
ProtocolOnly 14 pages are availabe for public view
 |  | from | 37 |  |  |
| | | from | 37 | | |
Abstract
Uterine cancer known as one of the most common gynecologic malignancies in developed countries, with the incidence of 14.7 per 100,000 women and the mortality rate of 2.3 per 100,000. The incidence of uterine cancer has also increased in developing countries to be the second most common gynecologic malignancy after cervical cancer.
Human epidermal growth factor receptor 2 (ERBB2, formerly HER2/neu, c-erbB2), is one of a family of 4 membrane tyrosine kinases (TKs), HER2 augmentation and resultant HER2 protein overexpression have been related to important tumor cell proliferation and survival pathways, several drugs have been developed to target the pathway HER 2, and the detection of HER2 has become a routine prognostic and predictive factor in breast cancer.
Uterine carcinomas, specifically adenocarcinomas, are relatively uncommon tumors that overexpress HER2/neu. Reports of the percentage of endometrial adenocarcinomas that overexpress HER2/neu have ranged between 13% and >50% with the consensus residing at approximately 20%, with approximately half of that percentage associated with gene amplification.
This study aims to evaluate the proportion of HER2 overexpression in endometrial carcinoma and its correlation with other known relevant variable clinical outcomes.
In this study: All patients diagnosed as high grade endometrial carcinoma in the period from January 2014 till December 2018 with full medical records in Ain Shams University Oncology Hospital and in Early Cancer Detection Unit (ECDU) at Ain Shams University Hospital (ASUH).40 patients diagnosed as high grade endometrial carcinoma in different stages and types are extracted . The patients’ paraffin blocks tested for HER2 overexpression using immunohistochemistry test (IHC) for detection of HER2 proteins.
After statistical analysis it was found that:
No statistically significant difference in HER2 expressions between different histological types. No significant difference between HER2 expression between tumors which more than 5cm in size and those less than 5cm.
No statistically significant difference in HER2 expression in tumors with more than 50% myometrial invasion and those with invasion less than 50%. There was significant difference in HER2 expression between tumors had LVI and those without LVI. According HER2 expression in tumors with metastasis and those with no metastasis there was significant difference in HER2 expression between two groups. According HER2 expression in different surgical staging of tumor it was found that 8.3% of stage I cases with positive expression of HER2, 43.8% of stage III cases had expressed HER2 and 83.3% of stage IV cases positively expressed HER2 with statistically significant difference between three stages.
Comparisons between positive and negative expressed HER2 cases according OS and mean estimated survival time using Chi Square and Log Rank tests where there is no significant difference statistically.
So there was significant correlation between HER2 expression and tumor stages, LVI, lymph node invasion and tumor metastasis. No significant correlation between HER2 expression and DFS, OS, tumor types and myometrial invasion.